Results 151 to 160 of about 1,917,601 (292)

Is it severe asthma or asthma with severe comorbidities?

, 2017
Luisa Brussino,1 Paolo Solidoro,2 Giovanni Rolla1 1Allergy and Clinical Immunology, University of Torino and Mauriziano Hospital, 2SC Pneumologia U, AOU Città della Salute e della Scienza, Torino, Italy Abstract: Severe asthma is defined as asthma
Brussino L, Rolla G, Solidoro P
core  

Basophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology and Application of the Basophil Activation Test

Allergy, EarlyView.
ABSTRACT Basophils, the least abundant leukocytes, are increasingly recognised as potent immunomodulators. Upon activation, they rapidly release preformed granule‐associated mediators including histamine and lipid mediators such as LTC4, while cytokine production occurs over a longer timescale, contributing to downstream immune responses.
Jitesh Chauhan, Sofia Vlasova, Alicia Chenoweth, Debra H. Josephs, Heather J. Bax, Sophia N. Karagiannis   +5 more
wiley   +1 more source

Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Review of Efficacy, Safety, and Clinical Applications. [PDF]

J Inflamm Res
Bajeli M, Corsello A, Foti Randazzese S, Marseglia A, D'Agostino P, Rossi CM, Marseglia GL, Licari A.   +7 more
europepmc   +1 more source

Serum‐Proteomic Profiling Reveals Distinct Atopic Dermatitis Severity‐Linked Signatures

Allergy, EarlyView.
This study aimed to identify a set of serum biomarkers that robustly distinguish prespecified severe from mild atopic dermatitis groups. Serum proteomic profiling distinguishes severe from mild atopic dermatitis, revealing an epithelial enriched severity footprint linked to LDH‐associated tissue injury and Th2/Th22 inflammation.
Jag S. Lally, Takeshi Yoshida, Shan Gao, Xueya Cai, Donald Y. M. Leung, Lisa A. Beck, Anna De Benedetto   +6 more
wiley   +1 more source

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy

, 2018
Corrado Pelaia,1 Alessandro Vatrella,2 Andrea Bruni,1 Rosa Terracciano,3 Girolamo Pelaia1 1Department of Medical and Surgical Sciences, Section of Respiratory Diseases, “Magna Græcia” University of Catanzaro, Catanzaro, Italy ...
Vatrella A, Pelaia C, Terracciano R, Bruni A, Pelaia G   +4 more
core  

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres, Cristobalina Mayorga, Elizabeth J. Phillips, Adriana Ariza, Annick Barbaud, Patrizia Bonadonna, Mariana Castells, Gülfem Çelik, Knut Brockow, Lene H. Garvey, Inmaculada Doña, Jean‐Christoph Caubet, Francesca Mori, Jason Trubiano, Giorgia Marta, Antonino Romano, Ingrid Terreehorst, Asli Gelincik, Philip H. Li, Vito Sabato   +19 more
wiley   +1 more source

Depemokimab: toward biannual biologic therapy for severe eosinophilic asthma. [PDF]

Respir Res
Papavassiliou KA, Gogou VA, Papavassiliou AG.   +2 more
europepmc   +1 more source

Factors for Success and Failure of Allergen Immunotherapy (AIT) Trial Design in the Light of Evidence‐Based Medicine: Current Aspects 2026

Allergy, EarlyView.
ABSTRACT Allergen immunotherapy (AIT) has been acknowledged as the only disease‐modifying treatment for respiratory diseases since its introduction in 1911. Although the efficacy and safety have convincingly been established in numerous randomized clinical trials (RCTs), the AIT study results may vary substantially.
Roy Gerth van Wijk, Vera Mahler, Melanie Albrecht, Danilo di Bona, Benjamin Hofner, Jasper Kappen, Susanne Kaul, Graham Roberts, Mohamed H. Shamji, Stefan Vieths, Oliver Pfaar   +10 more
wiley   +1 more source

Severe Eosinophilic Asthma: From Immunopathology to Pharmacological Treatment. [PDF]

J Clin Med
Pastore D, Lupia C, Chiarella E, Piazzetta GL, Mazza G, Neri G, Petrone A, Bruni A, Longhini F, Garofalo E, Pelaia G, Pelaia C.   +11 more
europepmc   +1 more source

Mepolizumab Modifies Blood Eosinophil Proteome and Transcriptome in Severe Eosinophilic Asthma

Allergy, EarlyView.
This study investigates the effect of mepolizumab on the proteomic and transcriptomic profile of blood eosinophils in SEA patients. Mepolizumab reduces the migratory capacity and effector‐related molecular signatures of circulating eosinophils in SEA patients.
Pablo Miguéns‐Suárez, Sara Vázquez‐Mera, Laura Martelo‐Vidal, Marina Blanco Aparicio, Uxío Calvo Álvarez, Coral González Fernández, Mar Mosteiro Añón, Dolores Corbacho Abelaira, Tamara Hermida Valverde, Christian Calvo Henríquez, Susana B. Bravo, Lena Uller, Juan J. Nieto‐Fontarigo, Francisco J. Salgado, Francisco J. González‐Barcala   +14 more
wiley   +1 more source